


Charts to the statement at the Annual Shareholders' Meeting in Essen (Germany)

May 31, 2023 - 10:00 a.m.


Christian Kullmann, Chairman of the Executive Board of Evonik Industries AG

2022: a year full of new challenges

Geopolitics



**Supply
chain
hurdles**



**Energy
crisis**



**Inflation &
recession**

81 Cases of forces majeure
at suppliers in February

€2.4 bn higher
variable costs

0% Russian gas supplied
to Germany since Sept.


-4% lower
volumes

Evonik delivers: a robust performance in tough conditions

External sales	2022 vs. 2021	Adjusted net income
€18,488 million	↑ +24%	€1,054 million
Adj. EBITDA		Adjusted earnings per share
€2,490 million	↑ +4%	€2.26
Free Cash Flow		
€785 million	↓ -17%	

Successful start to the next phase of our strategic transformation

„Next Generation Evonik“ strategy...



...positions Evonik well for the future



Climate change as an opportunity: focused initiatives to reduce emissions


Long-term PPA with EnBW



150 MW from offshore wind farm as from 2026:

- Covering 33% of Evonik European electricity requirements
- Avoiding ~150 kt CO₂ emissions p.a.

Significant increase in share of green electricity¹



Important basis for 25% reduction in Scope 1&2 CO₂ emissions by 2030

1. Renewable energy as share of externally sourced electricity worldwide

Systematic portfolio alignment

Divestments



TAA & Betaine

- October 2022: **Divestment** of **TAA-Derivatives** business (Specialty Additives) to SABO
- July 2022: **Divestment** of U.S. **Betaines** business (Care Solutions) to Kensing LLC

Exit Performance Materials



1st step with Functional Solutions

- April 2023: **Sale Luelsdorf site &** cyanuric chloride business to ICIG
- Alkoxides (**biodiesel catalysts**) **integrated** into Division Smart Materials

Streamlined operating model



Animal Nutrition

- **Lean sales- and marketing organization**; better reflection of the Methionine business model
- **Increased agility** in inventory management and procurement

Sustainability as an opportunity: growth driver for our portfolio

Membranes for efficient gas separation




Product design to ensure easy recycling



Non-animal-derived collagen platform



Fully bio-degradable Rhamnolipids




1. Share of sales generated by Next Generation Solutions by 2030

Innovation as a key to success



Sales contribution Innovation Growth Fields



Investment in innovative projects in our key regions

Pharmaceutical lipids



New lipid production facility, Tippecanoe

- New **global-scale production** facility for pharma **lipids for new mRNA-based drugs** to go on stream in 2025
- The project is **funded by the US government**

North America



Green hydrogen



Pilot electrolysis plant in Herne

- For the production of green hydrogen as a **feedstock for IPDA production**
- Testing **novel electrolysis technology** with Siemens Energy
- Funded by the **German Ministry of Education and Research**

Europe



Battery materials



Expansion of fumed aluminum oxides plant in Yokkaichi

- Expansion of production facility for **specialty aluminum oxides** to serve fast-growing battery and powder coating markets
- Funded by the **Japanese Government**

Asia-Pacific



Diversity and a performance culture to shape our future



Gender diversity


23% women in executive and senior management positions with women and **30%** on other manager levels by 2023

Intercultural mix

20% in executive and **35%** in senior management positions¹ by 2023

1. Employees whose nationality is not German

Stable dividend and high dividend yield of around 6 percent



1. Calculated at closing price Dec. 31, 2022 = €17.94


Evonik share price performance in 2022 and 2023

Share price development 2022

Evonik: -37%

DJ Stoxx Chemicals 600: -17%

MDAX: -28%




Share price development 2023¹

Evonik: +9%

DJ Stoxx Chemicals 600: +7%

MDAX: +10%



1. Share price development YTD up to May 22, 2023

Weak 1st quarter; outlook for 2023 confirmed

Weak business development in the first quarter, as expected



Price increases compensated for higher variable costs



Sales:
€ 4,005 million



Adj. EBITDA:
€ 409 million




Adj. earnings per share:
€ 0.25



Outlook FY 2023

Adj. EBITDA (in € million)





EVONIK

Leading Beyond Chemistry